Xencor Inc
NASDAQ:XNCR
Xencor Inc
NASDAQ:XNCR
Price:
20.36 USD
-4.59%
Market Closed
Updated:
May 15, 2024
Section:
Relative Value
The Relative Value of one
XNCR
stock under the Base Case scenario is
34.02
USD.
Compared to the current market price of 20.36 USD,
Xencor Inc
is
Undervalued by 40%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
XNCR
Relative Value
Base Case
34.02
USD
Undervaluation 40%
Valuation Multiples
Multiples Across Competitors
XNCR Competitors Multiples
Xencor Inc Competitors
Xencor Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Xencor Inc
NASDAQ:XNCR
|
1.3B USD | 7.7 | -9.4 | -5.9 | -5.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.4B USD | 5.3 | 59.2 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
167B USD | 5.7 | 44.4 | 18.7 | 30.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.4B USD | 11.2 | 30.5 | 24.6 | 25.8 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.5B USD | 8.3 | 28.1 | 22.8 | 25.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.3B USD | 3.1 | 174.2 | 7 | 9.2 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
49.1B USD | 9.5 | -8.2 | -9 | -8 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33B USD | 3.4 | 28.3 | 14.4 | 18 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.6T KRW | 18.2 | 73.8 | 45.2 | 62.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
